tiprankstipranks
Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
PremiumThe FlyKymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
2M ago
Kymera Therapeutics price target raised to $52 from $45 at Guggenheim
Premium
The Fly
Kymera Therapeutics price target raised to $52 from $45 at Guggenheim
2M ago
U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
Premium
The Fly
U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
2M ago
Kymera Therapeutics announces three presentations at EOTC-NI-AACR
PremiumThe FlyKymera Therapeutics announces three presentations at EOTC-NI-AACR
2M ago
Kymera Therapeutics announces FDA clearance of IND application for KT-621
Premium
The Fly
Kymera Therapeutics announces FDA clearance of IND application for KT-621
3M ago
Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
Premium
The Fly
Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
3M ago
Wolfe upgrades Kymera Therapeutics, calls ‘great long-term trade’
PremiumThe FlyWolfe upgrades Kymera Therapeutics, calls ‘great long-term trade’
4M ago
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
4M ago
Kymera Therapeutics TBA Spot Secondary priced at $44.75
Premium
The Fly
Kymera Therapeutics TBA Spot Secondary priced at $44.75
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100